Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 2/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4746611 | 1.00 | TAAR1 (0.42) | TAAR1NQO2MTNR1AMTNR1BSLC6A4 | |
| SCHEMBL15158492 | 0.94 | NQO2 (0.43) | TAAR1NQO2MTNR1AMTNR1BSLC6A4 | |
| SCHEMBL3143094 | 0.89 | NQO2 (0.43) | NQO2MTNR1AMTNR1BSLC6A4CHRM2 | |
| SCHEMBL537790 | 0.89 | NQO2 (0.43) | NQO2MTNR1AMTNR1BSLC6A4CHRM2 | |
| SCHEMBL3162728 | 0.89 | NQO2 (0.43) | NQO2MTNR1AMTNR1BSLC6A4CHRM2 | |
| SCHEMBL15180378 | 0.87 | TAAR1 (0.41) | TAAR1NQO2MTNR1AMTNR1BSLC6A4 | |
| SCHEMBL3163151 | 0.87 | TAAR1 (0.41) | TAAR1NQO2MTNR1AMTNR1BSLC6A4 | |
| Hydrochloric Acid SCHEMBL9427134 | 0.87 | KCNN2 (0.42) | NQO2MTNR1AMTNR1BDRD5 | |
| SCHEMBL14845340 | 0.82 | HTR2A (0.43) | TAAR1NQO2MTNR1AMTNR1BSLC6A4 | |
| SCHEMBL15158458 | 0.81 | NQO2 (0.41) | TAAR1NQO2MTNR1AMTNR1BSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476426-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2013-07-02 | — | — | US | disclosed |
| US-8415468-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2013-04-09 | — | — | US | disclosed |
| US-8288581-B2 | Process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2012-10-16 | — | — | US | disclosed |
| US-8278440-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2012-10-02 | — | — | US | disclosed |
| US-20120208996-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120116112-A1 | PROCESS FOR THE PREPARATION OF FUNCTIONALISED BENZOCYCLOBUTENES, AND APPLICATION IN THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2012-05-10 | — | — | US | disclosed |
| US-20110294999-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2011-12-01 | — | — | US | disclosed |
| US-20110201805-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201805-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | CYP4F2, CYP2F1, CYP2D6 | TAAR1 2732/4885NQO2 553/4885MTNR1A 2929/4885 |
| US-20120208996-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4F2, CYP2F1, CYP2D6 | TAAR1 2732/4885NQO2 553/4885MTNR1A 2929/4885 |
| US-20110294999-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4F2, CYP2F1, CYP2D6 | TAAR1 2732/4885NQO2 553/4885MTNR1A 2929/4885 |
| US-20120116112-A1 | PROCESS FOR THE PREPARATION OF FUNCTIONALISED BENZOCYCLOBUTENES, AND APPLICATION IN THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4F2, CYP2B6, CYP4F8 | TAAR1 1641/4885NQO2 1201/4885MTNR1A 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.